New cancer drug enters human testing for advanced tumors
NCT ID NCT06198426
Summary
This early-stage study tested a new cancer drug called IBI3004 in adults with advanced solid tumors that cannot be removed by surgery. The main goal was to find the highest safe dose that patients could tolerate. Researchers also looked at how the drug affected the cancer and monitored for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiang Su Province Hospital
Nanjing, Jiangsu, 210024, China
-
Liverpool Hospital
Sydney, New South Wales, 2170, Australia
-
Scientia Clinical Research Ltd
Randwick, New South Wales, 2770, Australia
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
-
Westmead Hospital
Sydney, New South Wales, 2170, Australia
Conditions
Explore the condition pages connected to this study.